Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study)-Reference-Cited by-同舟云学术

Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study)

Published:2019-01-31 Issue:4 Volume:109 Page:409-417
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Murakami Hirokazu,Kasamatsu Tetsuhiro,Murakami Jun,Kiguchi Toru,Kanematsu Takeshi,Ogawa Daisuke,Takamatsu Hiroyuki,Handa Hiroshi,Ozaki Shuji,Miki Hirokazu,Takahashi Takeshi,Takeo Takaaki,Yamauchi Tatsuya,Morishita Takanobu,Kosugi Hiroshi,Shimizu Kazuyuki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-019-02607-z/fulltext.html

Reference21 articles.

1. Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet J-G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.

2. Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist. 2011;16:388–403.

3. Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida S, Nakaya A, et al. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. Int J Hematol. 2018;107:541–50.

4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.

5. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, FIRST Trial Team, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma;Leukemia & Lymphoma;2024-05-30

2. Multiple Myeloma: Current Advances and Future Directions;The Kitakanto Medical Journal;2020-08-01

3. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma;International Journal of Molecular Sciences;2020-07-15

4. Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation;International Journal of Hematology;2019-07-19

5. Correction to: Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study);International Journal of Hematology;2019-05-22